// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
GrimAge predicts all-cause mortality better than chronological age and earlier clocks
Lu et al. Aging 2019; replicated across multiple cohorts.
Module 07 · The Epigenome and Methylation Clocks →A
EpiSign-style methylation profiling is a clinically actionable diagnostic for syndromic intellectual disability
>100 syndromes with validated episignatures; widely reimbursed in CA, EU.
Module 07 · The Epigenome and Methylation Clocks →B
Partial reprogramming (cyclic OSK) can reverse epigenetic age in human cells
Sarkar 2020, Lu 2020, Browder 2022 — strong cell/mouse evidence; no published human in-vivo trials yet.
Module 07 · The Epigenome and Methylation Clocks →C
Lowering your methylation-age via diet and exercise reduces personal mortality risk
Plausible from epidemiology; no RCT with a hard endpoint has demonstrated it.
Module 07 · The Epigenome and Methylation Clocks →D
Consumer methylation-age tests give individuals reliable biological-age estimates suitable for tracking interventions
Test-retest reliability and platform variability are substantial; useful for population research, weak for individual longitudinal claims.
Module 07 · The Epigenome and Methylation Clocks →